Assessment of sleep quality, anxiety, depression, and quality of life in Behçet’s disease

The Egyptian Journal of Bronchology

Table 11 Correlation of disease duration, disease severity, VDI, and BDCAF with PSQI components for Behçet’s Disease group (n = 30)

	Disease duration		Clinical Severity Score		VDI		BDCAF
	r	P	R	P	r	P	r	P
Sleep Quality	0.112	0.557	0.212	0.261	0.193	0.307	0.266	0.155
Sleep onset latency	0.162	0.393	0.191	0.311	0.261	0.163	0.211	0.263
Sleep duration	0.065	0.733	0.043	0.822	0.163	0.389	0.102	0.593
Sleep efficiency	-0.007	0.972	0.118	0.534	0.177	0.349	0.166	0.380
Sleep disturbance	0.092	0.629	0.240	0.200	0.200	0.290	0.252	0.178
Sleep medications	-0.061	0.774	-0.003	0.978	0.031	0.871	0.090	0.635
Daytime dysfunction	-0.036	0.849	0.171	0.365	0.128	0.500	0.179	0.343
PSQI score	0.141	0.459	0.180	0.340	0.278	0.137	0.245	0.192

Correlation for variables in the study was determined with spearman’s correlation. r Correlation coefficient rho. P-value: was significant if < 0.05. Clinical Severity score Krause’s Behçet’s disease activity assessment, VDI Vasculitis damage index, BDCAF Behçet's Disease Current Activity Form, PSQI Pittsburgh Sleep Quality Index